Kornimate/medical-research-clean huggingface dataset:
health consequences of wintering in the french southern and antarctic territories

Conditions: Environmental Exposure; Winter Depression; Endocrine System Diseases; Sleep Disorder; Immunologic Activity Alteration

Summary: polar stays expose people to extreme climate, isolation and confinement. the combination of these factors induces psychological disorders, sleep disorders, immune and endocrine disturbances, and deficiencies. in the taaf, (french southern and antarctic lands) two types of population coexist: winter residents, exposed to these stressors over long periods, and country people, who benefit from milder conditions and only make short stays. in this context, the investigators have decided to set up this cohort study with the objective of comparing the state of health of the winterers of the taaf from 2012 to 2017 with that of the country people of the same period, before their stay, during and the year following their return.

participants will answer to a questionnaire. this questionnaire will determinate participants health about following areas : psychological disorders, sleep disorders, immune and endocrine disturbances, and any deficiencies.

Eligibility criteria:
inclusion criteria: for the exposed group are: * to have carried out one or more wintering in one of the districts of the taaf, that means a stay of at least six consecutive months including winter; * have started their first wintering between 01jan2012 and 31dec2017; * know how to read and write french. for the non-exposed group are: * to have taken part in one or more summer campaigns between 01jan2012 and 31dec2017; * never have overwintered; * not having been refused wintering for health reasons or following psychological tests; * knowing how to read and write french. exclusion criteria: * persons under guardianship or guardianship, deceased persons, persons refusing to participate in the study
physicians work distribution in a danish emergency department

Conditions: Time Usage of ED Physicians

Summary: physicians in the emergency department spend their time on interviewing and examining patients, file documentation, communication with colleagues about the patients. introduction of it technology aims to reduce the administrative workload. however it is the impression that more and more time are used behind the pc rather than at the side of the patient. the aim of this study is to describe how the time is distributed between different task for an ed physician, and to analyse whether there are differences in time distribution if the physician is working in the outpatient area versus admission area of the ed.


Eligibility criteria:
inclusion criteria: ed physicians employed in the ed department exclusion criteria: -
coadministration of measles-rubella and rotavirus vaccines

Conditions: Measles Antibody Seroconversion; Rubella Antibody Seroconversion; Rotavirus Geometric Mean Titer (GMT); Rotavirus Immunoglobulin A (IgA) Seropositivity

Summary: the investigators aim to establish the non-inferiority of concomitant administration of measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of measles seroconversion rates. the primary study hypothesis is the measles seroconversion rate as defined by the percentage of children seroconverting to measles with a measles serum antibody concentration of \>=1:120 at 8 weeks post vaccination after the concomitant administration of measles-rubella and rotavirus vaccines is non-inferior to that obtained when measles-rubella vaccine is given alone in children 9 months of age who have received a primary rotavirus vaccine series with the first dose between 6 and 10 weeks and the second at least 4 weeks later and are seronegative for measles antibody in the pre-vaccination sample.


Eligibility criteria:
inclusion criteria: * child 9 months of age eligible for measles-rubella vaccination * documented evidence of a primary rotavirus vaccine series with first dose between 6 and 10 weeks of age and second dose at least 4 weeks after first dose * healthy infants free of chronic or serious medical condition as determined by history and physical examination at time of study enrollment * parents/guardians of each participant are able to understand and follow study procedures and agree to participate in study by providing signed informed consent exclusion criteria: * hypersensitivity to any component of measles-rubella or rotarix vaccine which would preclude administration of the vaccine * history of intussusception, intestinal malformations, or abdominal surgery * known history of measles and/or rubella disease * history of previous receipt of measles and/or rubella vaccine * use of any immunosuppressive drugs or immunoglobulin and/or blood products since birth or anticipated during study period * current enrolment in any other intervention trial or use of any investigational drug or vaccine throughout the study period * any participant who reports planning to leave the study area before the completion of the study * acute diarrhea (defined as ≥3 loose stools within a 24-hour period) or vomiting (defined as projectile vomiting or any vomiting at the discretion of the clinician) at the time of enrollment or within the last 24 hours * acute febrile illness (defined as a temperature of ≥38°c) at the time of enrollment.

Keywords: rotavirus
effect of palmitoylethanolamide on proinflammatory markers in adults recently diagnosed with covid-19

Conditions: Inflammation; COVID19

Summary: two randomized controlled trials will be conducted to examine the effect of a food supplement on proinflammatory cytokines and biomarkers in an adult population recently diagnosed with covid-19 who are asymptomatic or experiencing only mild symptoms. the supplement, palmitoylethanolamide (pea), is marketed under the trademarked product with increased bioavailability and format versatility: levagen+™ (gencor pacific limited, irvine, ca). the supplement curcumin is marketed under the trademarked product with increased bioavailability: hydrocurc (gencor pacific limited, irvine, ca)

inflammation is at the core of many chronic conditions and exacerbates infectious conditions, and inflammatory responses appear to be key determinants of the severity of covid-19 infection. hence, controlling inflammation is considered a key strategy for slowing the progression of disease and tissue pathology. this research offers a natural, dietary approach to managing inflammation by reducing the mediators of inflammation. the beneficial effects of palmitoylethanolamide (pea) and for curcumin for reducing inflammation is documented in the research literature. the proposed research will expand this literature in a novel manner. the investigators propose to demonstrate the efficacy of these dietary supplements in individuals from a campus population with robust immune protection - those who recently tested positive for covid-19 but were asymptomatic or mildly symptomatic. since a college population is under many stressors which raise inflammatory profiles during the academic year, and since a college population is exposed to infectious agents on campus, maintaining strong protective immune system following a covid-19 infection is important.

Eligibility criteria:
inclusion criteria: * male and females 18-65 years old * generally healthy * able to provide informed consent * recent positive covid-19 test (per rt-pcr test)\* exclusion criteria: * unstable or serious illness (e.g. kidney, liver, git, heart conditions, diabetes, thyroid gland function, malignancy, hiv, lung conditions or chronic asthma) * serious mood disorders, neurological disorders such as ms, or cognitive damage * active smokers and/or nicotine or drug abuse * active, regular marijuana or other cannabinoid use, other street/recreational drug use * chronic past and/or current alcohol use (\>14 alcoholic drinks week) * allergic to any of the ingredients in active or placebo formula including peanuts, eggs or turmeric * pregnant or lactating woman * people medically prescribed to take drugs that would affect the immune and/or the inflammatory response * people who have had treatment (last 5 years) for cancer, or chronic use of steroids * bmi \>40

Keywords: palmitoylethanolamide curcumin
addressing problems in managing daily tasks due to poststroke cognitive impairments

Conditions: Cognitive Impairment; Stroke

Summary: the purpose of this study is to investigate feasibility aspects of an intervention targeting problems in managing daily tasks due to mild-to-moderate poststroke cognitive impairments. we will specifically address uncertainties related to intervention content and delivery, and trial design and conduct.


Eligibility criteria:
patients: inclusion criteria: * first-ever symptomatic stroke, * age ≥ 18 years, * residence in frederiksberg municipality, denmark, * independent in pre-stroke everyday life (≤ 2 points on the modified rankin scale, mrs), * experiencing problems in performing adls due to cognitive impairment; these problems are expected to still be present at hospital discharge, * medical condition allows commencement of rehabilitation focused on adl and cognition * fully aware or mild-to-moderate unawareness of deficits (≤ 2 points on the bisiach anosognosia scale, bas), * a global cognitive function corresponding to ≥ 17 points on the montreal cognitive assessment, moca, * ≤ 10 points on the depression subscale of the hospital anxiety and depression scale, hads, * able to provide informed consent, as evaluated by the recruiting healthcare professional(s), * logistically possible to perform baseline assessments and create an individualised intervention plan during hospital stay * provides informed consent exclusion criteria: * psychiatric conditions causing difficulties or preventing participation, as evaluated by the recruiting health care professional(s) * communication problems causing difficulties or preventing participation, as evaluated by the recruiting healthcare professional(s) caregivers: inclusion criteria: * appointed as close carer (by a patient who consented to participate), * age ≥18y, * provides informed consent. exclusion criteria: -communication problems or other issues causing difficulties in participation as evaluated by the recruiting healthcare professional(s). patients without a close carer will not be excluded. clinical staff: inclusion criteria: * appointed as local project managers, or ots or nps who conduct assessments or deliver the intervention in the participating centres, * provides informed consent. exclusion criteria: - unable to to follow a preliminary english version of the intervention manual.

Keywords: occupational therapy neuropsychology stroke rehabilitation cognitive rehabilitation activities of daily living (adl)
pa moves trial - pcp participants

Conditions: Behavior; Physical Activity

Summary: the purpose of this voluntary research study is to determine the impact of an echo intervention on the likelihood that rural primary care providers (pcp) will refer their physically inactive patients to be more active.

people living in rural areas are diagnosed and die from cancer at higher rates than people living in cities. physical activity has been shown to decrease the risk and occurrence of a variety of cancers, including bladder, breast, colon, endometrial, gastric, kidney, and prostate cancers. being inactive can cause over 10% of breast and colon cancer cases. compared to people living in cities, people living in rural areas tend to be less physically active. they're also more likely to be overweight/obese or have diabetes. adults who are overweight, obese, or diabetic often have changes in the way their bodies deal with insulin, glucose metabolism, and inflammation. physical activity is thought to reduce the risk of cancer by improving these issues over time. pcps and their staff can identify a patient's need for more physical activity, but may not have the time or resources to give advice or assistance. we have set up a telephone-based physical activity coaching program, called the moveline, to give inactive patients advice and assistance in becoming more physically active. the purpose of this study is to determine if an echo intervention will impact the likelihood that pcps will refer patients to the moveline for physical activity coaching. approximately 32-48 providers will take part in this research study.

Eligibility criteria:
inclusion criteria: 1. primary care providers or adjunct faculty from primary health network (phn) or upmc clinics serving rural populations 2. must be able to provide and understand informed consent exclusion criteria: 1. primary care providers or adjunct faculty not from phn or upmc clinics
effect of spiriva® 18 microgram on health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (copd) and proven hyperinflation

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: * primary objective of this observational study was to gain insights into the effects of therapy with spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (copd) and demonstrated hyperinflation. * secondary objective was to obtain safety data regarding adverse events.


Eligibility criteria:
inclusion criteria: * women and men with diagnosis of chronic obstructive pulmonary disease (copd) with a thoracic gas volume (tgv) \> = 120% as measured by body plethysmography * only patients who have not yet been treated with spiriva® 18 micrograms can be included in the study. exclusion criteria: * patients who presenting the general and specific contraindications mentioned in the patient information and prescribing information
defining predictors of rt response to vedolizumab in ibd

Conditions: Crohn Disease of Small Intestine

Summary: the overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel cd. there is an unmet need to identify response to vedolizumab in small bowel cd using objective endpoints. current data suggest that mr enterography may meet this unmet need. there is an additional unmet need to develop predictive models incorporating both clinical and baseline radiological and endoscopic variables with higher discriminatory performance in identifying longer term clinical remission with vedolizumab. finally, this proposal is strengthened by the exploratory studies which may identify new proteomic biomarkers that correlate with longer term radiological response with vedolizumab reflecting its latency of response. if successful, these serum biomarkers may guide a personalized approach to the treatment of small bowel cd with vedolizumab, allowing early identification of pnr, monitoring disease activity and the pharmacodynamics of vedolizumab.


Eligibility criteria:
inclusion criteria: * moderate to severe disease activity small bowel cd (small bowel only or ileocecal only) visible on mre * initiated on vedolizumab with/without thiopurines or methotrexate * ≥18 years old exclusion criteria: * pregnancy * age \<18 * planned surgery prior to the first follow-up mre * inability to provide informed consent. * perianal cd will be excluded since assessment requires performance of additional mri of the pelvis. * individuals with colonic involvement other than involvement of the ascending colon and cecum. * inpatient scans will only be included if this is a mre and adequate small bowel distension with appropriate contrast has been achieved * if unable to provide informed consent * contraindications for mre including chronic kidney disease that precludes contrast administration, implanted medical devices that are contraindicated for mre.
pharmacokinetic study of single dose dutasteride in healthy subjects

Conditions: Alcohol Related Disorders; Alcoholism; Alcohol Abuse

Summary: to monitor the inhibition of 5a-reductase (5ar) enzyme activity at 1, 3, 7, 14, 21, 28 and 42 days following administration of a single dose of dutasteride (2, 3, or 4 mg) by measuring the change in blood levels of 3a-androstanediol glucuronide (3a-diolg) and the ratio of dihydrotestosterone (dht) to testosterone. to accomplish this aim, an open-label, between-subjects dose comparison study design will be employed with subjects receiving a 2, 3, or 4 mg dosage. subjects (up to n=40 enrolled to allow a minimum of 24 completers) will be randomly assigned to one of the 3 dose levels. results of this study will inform the dose selection for a subsequent placebo-controlled, within-subject, crossover study of dutasteride on the effects of alcohol. a secondary aim of this study is to examine the correlation of a genetic variation in the type i 5ar gene and baseline dht/t ratio and effect of dutasteride at day 3. a variation in this gene which is one of the targets of dutasteride has been reported to be associated with higher baseline levels of dht.

alcohol abuse and dependence remain important public health problems. the chemical mechanisms by which alcohol affects the nervous system are not well understood. recent theories suggest that alcohol stimulates release of "neuroactive" steroid hormones which are important mediators of alcohol effects. this proposal seeks to identify the most appropriate dosage of an fda approved medication, dutasteride, which blocks the metabolism of steroid hormones, so that we can use dutasteride as a pharmacologic probe of the biochemistry of alcohol effects in human subjects in a subsequent study.

Eligibility criteria:
inclusion criteria: * subjects will be healthy males volunteers who are 21-55 years old and have a bmi \>18.5 and \<32.5. all enrolled subjects will have signed irb approved consent. exclusion criteria: * subjects cannot have a current or past dsm-iv diagnosis of alcohol or drug dependence, current or past 12-months diagnosis of alcohol or drug abuse or major psychiatric disorder, neurological illness, have had a hypersensitivity reaction to dutasteride, physical exam evidence of liver dysfunction, currently be using psychotropic medications or medications that are known to influence steroid hormone levels or metabolism. nicotine-dependent subjects will be excluded to avoid the confounding effects of nicotine withdrawal during day-long laboratory sessions which are part of the planned alcohol administration study as well as effects of tobacco use on metabolism. subjects who do not agree to use barrier contraception for 1 week after administration of dutasteride will be excluded

Keywords: steroid 5areductase genetic polymorphism gaba receptor
clinical trial of sacral neuromodulation for treatment of refractory overactive bladder (oab)

Conditions: Refractory Overactive Bladder

Summary: evaluate the long-term clinical effectiveness and safety of the pins sacral neuromodulation to patients with refractory overactive bladder.


Eligibility criteria:
inclusion criteria: * age greater than 16 years oab and/or oab symptoms refractory to standard medical therapy 100ml bladder capacity with normal upper urinary tract good surgical candidate able to complete study documentation and return for followup evaluation exclusion criteria: * neurological conditions stress urinary incontinence oab symptoms caused by urinary tract infections

Keywords: pins sns oab
safety and efficacy of delayed manipulation after xiaflex treatment in subjects with dupuytren's contracture

Conditions: Dupuytren's Disease

Summary: the purpose of this study is to determine if of manipulation of digits following collagenase injection for treatment of dupuytren's contracture is effected by the amount of time between injection and manipulation.

patients with metacarpophalangeal joint contractures caused by dupuytren's disease will be evaluated as to the timing of the finger manipulation procedure that is performed following collagenase injection. three groups will be evaluated: group 1 will have the manipulation procedure on the day following collagenase injection, group 2 will have the manipulation procedure on the second day following collagenase injection,and group 3 will have the manipulation procedure on the fourth day following collagenase injection,

Eligibility criteria:
inclusion criteria: * adult subjects (\> 18 years) of either gender with an metacarpophalangeal joint contracture and a palpable cord of \> 20 degrees of a digit (excluding the thumb) due to dupuytren's contracture exclusion criteria: * any subject who has had prior surgical, percutaneous needle aponeurotomy or xiaflex treatment for dupuytren's contracture. * any subject using anti-coagulant therapy other than low dose aspirin (up to 150mg/day). * any subject in the opinion of the md investigators with chronic, severe or terminal medical illness which would make them unsuitable for study participation. * any subject with known allergy to xiaflex (clostridial collagenase). * any subject who cannot conform to the study visit schedule

Keywords: dupuytren dupuytren's
use of a liquid biopsy signature to detect early-onset gastric cancer

Conditions: Gastric Cancer

Summary: early-onset gastric cancer (eogc) is a lethal malignancy with a poor prognosis. it differs from late-onset gastric cancer (logc) in clinical and molecular characteristics. the current strategies for eogc detection have certain limitations in diagnostic performance due to the rising trend in eogc. hence, identifying novel eogc bioindicators is crucial.

due to widespread gastric cancer (gc) detection efforts and timely interventions (removal of precancerous lesions and early-stage gc), the gc-associated mortality rate has declined worldwide. however, epidemiological studies show rising gc incidences among young adults (\< 50 years old) without familial or hereditary origin. this illness, known as early-onset gc (eogc), comprises 20-30% of new gc diagnoses, mainly among individuals aged 30-40 years; the median overall survival time is 11.7 months. although the underlying cause behind this trend is poorly understood, there is a general understanding that eogc epidemiologically, biologically, and pathologically differs from late-onset gc (logc, ≥ 50 years). therefore, eogc patients require clinical assessment and intervention distinct from those applied in logc. of note, several population-based epidemiological studies have suggested that eogc patients exhibit significantly different behaviors from logc patients. eogc patients are more likely to have earlier lymph node and distal metastasis than logc patients during disease progression. these tough challenges raise clinical concerns: eogc is more aggressive than logc; thus, a delayed diagnosis can severely affect patient survival outcomes. moreover, the current approaches to gc detection, such as cea, hp serology, and pepsinogen (pg), are insufficient for detecting early-stage gc and have yet to be investigated in young individuals with eogc. accordingly, these limitations strongly underscore the necessity to establish potent alternative indicators that facilitate the timely detection of eogc.

Eligibility criteria:
inclusion criteria: * having signed informed consent * 50 years old ≥ age ≥ 18 years old * histologically confirmed gastric adenocarcinoma exclusion criteria: * other previous malignancy within 5 year * surgery (excluding diagnostic biopsy) within 4 weeks prior to study * pregnancy or lactation period * legal incapacity